Clinical Trial Update: A Phase I/II Study of Ganetespib in Combination With Doxorubicin [Phase 1, Phase 2]

View source ↗

Summary

A phase I/II study of ganetespib in combination with doxorubicin in small cell lung cancer was terminated, with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Doxorubicin (doxorubicin)
• Ganetespib (ganetespib)

Snippet

Sponsor: Georgetown University | Conditions: Cancer, Small Cell Lung Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2018-02-07